DrugDev Integrates Technology Solutions, Collaborates With Transcelerate And INC Research, Inc., Adds Key Executives, Accelerates The Innovation Lab, And Continues Rapid Growth In First Half Of 2015

9 of the top 10 and 4 of the 5 largest CROs trust DrugDev technologies and services to do more trials

KING OF PRUSSIA, Pa. & LONDON--(BUSINESS WIRE)--During the first half of 2015, DrugDev made significant strides toward helping more sponsors, CROs and investigators do more trials together through industry-wide collaboration, standardization, and a beautiful technology experience. Among other accomplishments, DrugDev:

• Integrated the leading specialized site payments provider, CFS Clinical, and the award-winning TrialNetworks platform into DrugDev’s unified solution suite.
• Collaborated with TransCelerate to develop and host the Investigator Registry (launching this year) using the DrugDev Golden Number universal identifier.
• Accelerated the Innovation Lab, directed by Executive Chairman Hugo Stephenson, MD, as a technology incubator for innovative clinical solutions.
• Welcomed new senior executives to its leadership team and named Dr. Jeffrey Kasher Chairman of its Advisory Board.
• Grew its customer roster by 20%, moved to a new corporate headquarters in King of Prussia, and doubled the size of its Boston office for the second time in twelve months.

DrugDev President and CEO Ibraheem (Ibs) Mahmood said, “Our message is simple: let’s bring companies and sites together with technology that fundamentally changes the way clinical trials are run. 2015 was a strong year for our company and for the industry in regards to standardization and collaboration, but let’s be clear – we have a long way to go. Still, it is obvious that the industry is eager for, and even demanding, change. I believe we will soon look back on these early days of the year as a real indicator that things had finally begun to move in the right direction, and I’m proud that DrugDev is in the middle of it all.”

2015 DrugDev highlights include:

Technology Leadership

DrugDev’s unified suite of SaaS-based solutions enables sponsors and CROs to improve quality and efficiency of clinical trials from planning through closeout:

• DrugDev TrialNetworks – Optimize clinical operations with a site-facing platform for training, engagement, process and tracking
• DrugDev Payments (formerly CFS Clinical) – Ensure sites are paid accurately and on time with transparent Sunshine Act reporting and global tax services
• DrugDev SiteStart – Find global investigators in the DrugDev network and activate sites faster with contracting and essential regulatory document services
• DrugDev Data Solutions– Match and master investigator and site profiles using the DrugDev Golden Number universal identifier

Industry Collaborations

TransCelerate – Building on the work of the Investigator Databank, TransCelerate selected DrugDev to develop and host its Investigator Registry (launching this year). By using the DrugDev Golden Number, the Investigator Registry will enable TransCelerate Member Companies to pool data in a centralized, cloud-based resource to share mastered investigator and site records.

INC Research – INC became the first CRO to integrate with the DrugDev SiteCloud platform and the Golden Number to improve efficiencies for feasibility, site selection and study start-up, payments and contracting for its sponsor customers in global clinical trials.

Corporate Growth & Expansion

Pharmaceutical development executive Jeffrey Kasher, Ph.D. joined DrugDev as Chairman of the Advisory Board, bringing 28 years of leadership experience at Eli Lilly to help guide the future development of DrugDev technology solutions.

DrugDev appointed global change management expert Nick Watling as Chief Business Officer to organize and optimize the company as it accelerates growth to meet escalating demand.

DrugDev also invested in expanding its product management, customer services and sales teams with senior industry experts while growing to approximately 250 employees.

Business & Industry Recognition

Ibs Mahmood was one of only six executives worldwide to win a “Disrupter” award in the 2015 PM360 ELITE Award Program, which honors the most influential people in the global healthcare industry.

Melissa (Liss) Easy, DrugDev Founder and President of SiteStart, was named “Woman of the Year” by Partnerships in Clinical Trials as well as a Philadelphia Business Journal “40 Under 40.”

Industry Education

DrugDev sponsored, keynoted and presented at top industry conferences including the DIA Annual Meeting, the Summit for Clinical Ops Executives (SCOPE), MAGI Clinical Research Conference, Clinical Innovation Conference, and the ACRP Global Conference and Exposition.

In addition, DrugDev continued its popular Investigator View webinar series which provides an unfiltered forum for investigators to share their opinions on important aspects of clinical research. Presentation topics included personalized oncology medicine (featuring the Sarah Cannon Research Institute), virtual clinical trials (featuring Coastal Carolina Research Center), and minorities in clinical research (with Emerson Clinical Research Institute).

Visit drugdev.com to begin a conversation about how sponsors, CROs and sites can make the second half of 2015 even more successful by working together to do more trials.

About DrugDev

DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev technology to do more trials at drugdev.com. Connect with DrugDev on LinkedIn and Twitter.